Phibro Animal Health (PAHC) AI Stock Analysis

• Market Cap: $1.78B
• Dividend Yield: 1.17%
• Average Volume (3M): 280.99K
• Price to Earnings (P/E): 26.3
• Beta (1Y): 1.03
• Revenue Growth: 33.71%
• EPS Growth: 289.48%
• Country: US
• Employees: 1,940
• Sector: Healthcare
• Sector Strength: 45
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): 0.73
• Shares Outstanding: 20,447,575
• 10 Day Avg. Volume: 340,902
• 30 Day Avg. Volume: 280,989
• PEG Ratio: 0.01
• Price to Book (P/B): 3.62
• Price to Sales (P/S): 0.80
• P/FCF Ratio: 24.73
• Enterprise Value/Market Cap: 1.33
• Enterprise Value/Revenue: 1.68
• Enterprise Value/Gross Profit: 5.40
• Enterprise Value/Ebitda: 13.61
• 1Y Price Target: $39.75
• Price Target Upside: -9.16% Downside
• Rating Consensus: Hold
• Number of Analyst Covering: 4
• EPS Forecast (FY): 2.63
• Revenue Forecast (FY): $1.46B

• Rating: 71 Outperform
• Price Target: $46.00 ▲(5.12% Upside)

Phibro Animal Health's strong earnings call performance and positive technical indicators are significant strengths, contributing to a favorable outlook. However, high leverage and cash flow challenges, along with a high P/E ratio, present risks that temper the overall score.

Positive Factors

Animal Health Segment Growth

The significant growth in the Animal Health segment underscores strong market demand and effective product offerings, positioning the company well for sustained revenue expansion.

New Product Launch

The introduction of new products like Restoris enhances the company's product portfolio and supports long-term growth in the companion animal market.

Increased Earnings Guidance

The raised earnings guidance reflects confidence in operational performance and strategic initiatives, indicating strong future profitability.

Negative Factors

High Leverage

High leverage can limit financial flexibility and increase risk, potentially impacting the company's ability to invest in growth opportunities.

Negative Free Cash Flow Growth

Negative free cash flow growth indicates challenges in cash generation, which could constrain investment in strategic initiatives and debt reduction.

Flat Revenue Guidance

Unchanged revenue guidance suggests potential market challenges or headwinds, indicating caution in revenue growth expectations.

Phibro Animal Health Business Overview & Revenue Model

Company Description

Phibro Animal Health Corporation develops, manufactures, and supplies a range of animal health and mineral nutrition products for livestock primarily in the United States. It operates through three segments: Animal Health, Mineral Nutrition, and Performance Products. The company develops, manufactures, and markets products for a range of food animals, including poultry, swine, beef and dairy cattle, and aquaculture. Its animal health products also comprise antibacterials that are biological or chemical products used in the animal health industry to treat or to prevent bacterial diseases; anticoccidials primarily used to prevent and control the disease coccidiosis in poultry and cattle; anthelmintics to treat infestations of parasitic intestinal worms; and anti-bloat treatment products for cattle to control bloat in animals grazing on legume or wheat-pasture. In addition, the company offers nutritional specialty products, which enhance nutrition to help improve health and performance; and vaccines to prevent diseases primarily for the poultry and swine markets. Further, it manufactures and markets formulations and concentrations of trace minerals, such as zinc, manganese, copper, iron, and other compounds; and various specialty ingredients for use in the personal care, industrial chemical, and chemical catalyst industries. The company sells its animal health and mineral nutrition products through local sales offices to integrated poultry, swine, and cattle integrators, as well as through commercial animal feed manufacturers, wholesalers, and distributors. It operates in the United States, Latin America, Canada, Europe, the Middle East, Africa, and the Asia Pacific. The company was formerly known as Philipp Brothers Chemicals, Inc. and changed its name to Phibro Animal Health Corporation in July 2003. Phibro Animal Health Corporation was incorporated in 2014 and is headquartered in Teaneck, New Jersey.

How the Company Makes Money

Phibro Animal Health generates revenue through the sales of its diverse range of animal health products, including vaccines, pharmaceuticals, and nutritional solutions. The company's revenue model is primarily based on direct sales to livestock producers, veterinarians, and feed manufacturers. Key revenue streams include the Animal Health segment, which contributes significantly through the sale of vaccines and medicated feed additives, and the Animal Nutrition segment, which focuses on specialty feed ingredients. Phibro also benefits from strategic partnerships with distributors and collaborations with research institutions to enhance product development and market reach. Additionally, the growing demand for animal protein and the increasing focus on animal health and welfare contribute positively to its earnings.

Phibro Animal Health Financial Statement Overview

Summary

Phibro Animal Health shows strong revenue growth and profitability with efficient operations. However, high leverage and negative free cash flow growth present potential risks. The company should focus on improving cash flow management and reducing debt levels to enhance financial stability.

Income Statement

Phibro Animal Health shows a solid revenue growth rate of 7.98% TTM, indicating strong market demand. The gross profit margin of 31.17% and net profit margin of 4.85% TTM reflect stable profitability, though there is room for improvement in net margins. EBIT and EBITDA margins are healthy at 6.08% and 12.35% TTM, respectively, suggesting efficient operations.

Balance Sheet

The company's debt-to-equity ratio of 1.96 TTM indicates high leverage, which could pose financial risks. However, a return on equity of 24.43% TTM shows effective use of equity to generate profits. The equity ratio of 22.49% TTM suggests moderate financial stability.

Cash Flow

Free cash flow growth is negative at -18.03% TTM, highlighting potential cash flow challenges. The operating cash flow to net income ratio of 0.28 TTM and free cash flow to net income ratio of 0.45 TTM indicate moderate cash generation relative to net income.

Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	1.40B	1.30B	1.02B	977.89M	942.26M	833.35M
Gross Profit	436.23M	399.94M	313.09M	298.24M	285.40M	271.38M
EBITDA	172.94M	146.85M	69.06M	106.03M	117.13M	110.21M
Net Income	67.82M	48.26M	2.42M	32.61M	49.17M	54.38M
Balance Sheet
Total Assets	1.39B	1.36B	982.18M	971.40M	931.70M	841.33M
Cash, Cash Equivalents and Short-Term Investments	85.27M	77.04M	114.61M	81.28M	91.25M	93.21M
Total Debt	785.10M	761.55M	525.46M	509.97M	470.48M	426.71M
Total Liabilities	1.07B	1.08B	725.54M	688.89M	669.26M	602.80M
Stockholders Equity	311.68M	285.68M	256.64M	282.51M	262.44M	238.53M
Cash Flow
Free Cash Flow	34.29M	41.83M	46.36M	-38.48M	-5.39M	18.99M
Operating Cash Flow	76.80M	80.12M	87.59M	13.31M	31.65M	48.31M
Investing Cash Flow	-306.77M	-288.69M	-48.19M	-74.02M	-22.58M	-18.58M
Financing Cash Flow	252.67M	207.13M	-6.77M	26.99M	16.34M	-17.00M

Phibro Animal Health Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 43.76
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For PAHC, the sentiment is Positive. The current price of 43.76 is above the 20-day moving average (MA) of 40.96, above the 50-day MA of 39.71, and above the 200-day MA of 28.06, indicating a bullish trend. The MACD of 1.21 indicates Negative momentum. The RSI at 63.69 is Neutral, neither overbought nor oversold. The STOCH value of 60.83 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for PAHC.

Phibro Animal Health Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
PAHC	71 Outperform	$1.78B	26.31	23.79%	1.17%	33.71%	289.48%
ZTS	70 Outperform	$52.99B	20.26	49.87%	1.66%	2.68%	11.51%
ELAN	69 Neutral	$10.68B	294.79	0.54%	―	3.08%	-82.39%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%

Phibro Animal Health Corporate Events

Phibro Animal Health Reports Strong Q1 Growth

Phibro Animal Health Corporation is a global leader in animal health and mineral nutrition, providing solutions to enhance the health of farm and companion animals. The company operates primarily in the animal health sector, offering products such as medicated feed additives, nutritional specialties, and vaccines.

Phibro Animal Health Corp’s Earnings Call Highlights Robust Growth

Phibro Animal Health Corp’s recent earnings call conveyed a generally positive sentiment, reflecting strong growth in its Animal Health segment and overall financial performance. The company celebrated successful new product launches, which contributed to an increased earnings guidance. However, the call also highlighted some challenges, such as a decline in Performance Products and rising corporate expenses. Despite strong Q1 results, the revenue guidance remained unchanged, indicating a cautious outlook moving forward.

Phibro Animal Health Reports Strong Q1 Sales Growth

On November 4, 2025, Phibro Animal Health Corporation held its annual stockholders meeting, where key decisions were made including the election of directors and approval of executive compensation. The company reported a strong start to fiscal 2026 with a 40% increase in net sales for the first quarter, driven by significant growth in its Animal Health segment. Phibro’s strategic initiatives and market demand have led to increased earnings guidance, highlighting its competitive positioning and commitment to long-term value creation.

The most recent analyst rating on (PAHC) stock is a Buy with a $46.00 price target. To see the full list of analyst forecasts on Phibro Animal Health stock, see the PAHC Stock Forecast page.

Phibro Animal Health Declares Quarterly Cash Dividend

On November 4, 2025, Phibro Animal Health Corporation announced a quarterly cash dividend of $0.12 per share for its Class A and Class B common stock, payable on December 17, 2025, to stockholders recorded by November 26, 2025. This announcement reflects Phibro’s continued commitment to returning value to its shareholders and may positively impact its market positioning by reinforcing investor confidence.

The most recent analyst rating on (PAHC) stock is a Buy with a $46.00 price target. To see the full list of analyst forecasts on Phibro Animal Health stock, see the PAHC Stock Forecast page.

Phibro Animal Health Corp’s Earnings Call Highlights Robust Growth

Phibro Animal Health Corp’s recent earnings call conveyed a robust performance, underscored by substantial growth in key areas, particularly the Animal Health segment. The company expressed optimism for the upcoming fiscal year, driven by the successful implementation of the Phibro Forward strategy. However, the call also highlighted challenges, including a decline in legacy MFA net sales and increased SG&A and interest expenses.

Phibro Animal Health Faces AI-Driven Risks Threatening Business Stability

Phibro Animal Health Corp faces significant risks associated with its use of machine learning and artificial intelligence, as these rapidly evolving technologies can lead to operational, compliance, and reputational challenges. The unpredictability of AI algorithms, which may produce irrelevant or biased results, poses potential legal and ethical issues. Any disruption in AI systems, whether internal or from third-party providers, could lead to operational delays and challenges. These factors collectively threaten to materially impact Phibro’s business operations, financial health, and market standing.

Phibro Animal Health Reports Strong Fiscal Year Results

Phibro Animal Health Corporation is a global leader in animal health and mineral nutrition, providing solutions to enhance the health of farm and companion animals. The company operates primarily in the animal health sector, offering a diverse portfolio that includes medicated feed additives, nutritional specialties, and vaccines.